Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

ISA Pharmaceuticals

Request full access

Developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections

Leiden, NetherlandsFounded 2004Biotech & Life Sciences

About ISA Pharmaceuticals

ISA Pharmaceuticals focuses on developing targeted, rationally designed immunotherapeutics for the treatment of cancer and persistent virus infections. The company operates in the biotechnology sector, primarily serving patients and healthcare providers. ISA Pharmaceuticals' business model revolves around the research, development, and commercialization of immunotherapy treatments. Revenue is generated through the sale of these treatments, as well as potential partnerships and licensing agreements with other pharmaceutical companies. The company is actively involved in clinical trials, such as the Phase II combination trial of its lead immunotherapy ISA101b. ISA Pharmaceuticals also adapts to emerging health crises, as evidenced by its development of ISA106 SLP therapeutic for COVID-19.

Source: Dealroom company data

At a glance

Status
Closed
Employees
5
Open positions
None listed
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Oncology, Immune System, Pay Per Result, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B, B2C

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Jul 2021 $29M $114M Invest-NL · Regeneron Pharmaceuticals —
DEBT✓Debt Oct 2019 $22M — European Investment Bank —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

ISA Pharmaceuticals website traffic

Latest recorded traffic for ISA Pharmaceuticals is 610 monthly website visits, up 5.2% over the last three months. ISA Pharmaceuticals's team grew 0% over the past year.

Latest monthly visits610 3-month web change+5.2% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

ISA Pharmaceuticals in the Leiden ecosystem

Live from Dealroom

The ISA Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Invest-NL
  • Regeneron Pharmaceuticals

Series B and later1 investor entered at this stage

  • European Investment Bank

Other known investors2 additional known investors

  • Aglaia BioMedical Ventures
  • Karl Rothweiler
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇳🇱 Netherlands · Leiden HQ
Book a demo for the full country breakdown

See ISA Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.